AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Transaction in Own Shares Mar 1, 2024

3232_dirs_2024-03-01_f9eaf99c-cb40-4eb1-8074-ea3d09dff474.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

Disclosure 443269

Orion - Changes in company's own shares

Orion Corporation: Transfer of 150,118 own B shares on 1 March 2024

ORION CORPORATION

STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES

1 MARCH 2024 at 18.50 EET

Orion Corporation: Transfer of 150,118 own B shares on 1 March 2024

In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2024 transferred altogether 150,118 Orion Corporation B shares held by the company as a share reward for earning period 2021–2023 to the persons belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022.

The price per share of the transferred shares is EUR 36.4279, which is the volume weighted average quotation of the Orion Corporation B share on 1 March 2024. Accordingly, the total transaction price of the transferred shares is EUR 5,468,483.49.

After the share transfer, the total number of own B shares held by Orion Corporation is 632,855.

Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 6 February 2019.

Orion Corporation

Liisa Hurme

President and CEO
Olli Huotari

SVP, Corporate Functions

Contact person:

Olli Huotari, SVP, Corporate Functions

tel. +358 10 426 3054

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.